Preclinical characterization of IPH45, a novel topoisomerase I inhibitor ADC targeting Nectin-4 for the treatment of Nectin-4 expressing tumors

被引：1
|
作者：
Remark, Romain
Bonnafous, Cecile
Chiossone, Laura
Soulas, Caroline
Perrier, Cyril
Habif, Guillaume
Bokobza, Sivan
Maguer, Aurelie
Courtois, Rachel
Lopez, Julie
Fenaux, Gregory
Benac, Olivier
Carrette, Barbara
Letay-Drouet, Robin
Bonifay, Raja
Augier, Severine
Simon, Lea
Rossi, Benjamin
Morel, Ariane
Represa, Agnes
Beltraminelli, Nicola
Morel, Yannis
Paturel, Carine
Vivier, Eric
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-6582
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6582
引用
收藏
页数：2
相关论文
共 36 条
  • [21] Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC).
    Ye, Ding-Wei
    Zhang, Jian
    Yang, Hua
    Yang, Jin
    Zheng, Tongsen
    Sun, Hongmei
    Wan, Xuechao
    Lan, Ge
    Sun, Guilan
    Zhang, Xiao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [22] Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors
    Zhang, J.
    Liu, R.
    Gao, S.
    Li, X.
    Chen, J.
    Yao, X.
    Fang, Y.
    Li, R.
    Zhang, M.
    Qiu, F.
    Li, Y.
    Liu, T.
    Huang, H.
    Zhang, X.
    Guo, H.
    Hu, B.
    Liu, J-Y.
    Yang, Q.
    Zhao, P.
    Wang, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S464 - S464
  • [23] Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer
    Carosino, Christopher
    Olson, Devra
    Snead, Katie
    Lee, Anthony
    Farr, Lauren
    Garg, Amit
    O'Day, Christine
    Trueblood, Esther
    Wright, Jennifer
    Bieda, Mark
    Caldwell, Charles
    Hensley, Kelly
    Allred, Sean
    Liu, Bernard
    Shimazaki, Masashi
    Sandall, Sharsti
    CANCER RESEARCH, 2022, 82 (12)
  • [24] Inducing complete and long-lasting tumor eradications at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation.
    Attinger-Toller, Isabella
    Probst, Philipp
    Bertrand, Romain
    Stark, Ramona
    Santimaria, Roger
    Grabulovski, Dragan
    Schlereth, Bernd
    Spycher, Philipp
    CANCER RESEARCH, 2022, 82 (12)
  • [25] BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies
    Mckean, M.
    Bendell, J. C.
    Petrylak, D. P.
    Powles, T. B.
    Sonpavde, G. P.
    Dickson, A.
    Dosunmu, L.
    Hennessy, M. G.
    Jeffrey, P.
    Rigby, M.
    West, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S500 - S501
  • [26] Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.
    McKean, Meredith
    Falchook, Gerald Steven
    Bendell, Johanna C.
    Bashir, Babar
    Palmisiano, Neil
    Watson, Roshawn
    McKenna, Mary-Anne
    Campbell, Carly
    Smethurst, Dominic Paul
    Jeffrey, Phil
    Kirui, Julius
    Arkenau, Hendrik-Tobias
    Fontana, Elisa
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Preclinical development of a B7-H3-targeting ADC with a novel DNA topoisomerase I inhibitor for solid tumors
    Li, Chenggang
    Yao, Jun
    Qu, Chen
    Li, Bing
    Zhang, Yu
    Shi, Rong
    Qiu, Yang
    Hua, Haiqing
    CANCER RESEARCH, 2023, 83 (07)
  • [28] A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies
    Papadopoulos, Kyriakos P.
    Dowlati, Afshin
    Dickson, Amy
    Hirschberg, Sandra
    Westrup, Sally
    Upadhyaya, Punit
    Cohen, Heather
    Hurov, Kristen
    Watson, Roshawn
    Hazard, Sebastien
    Smethurst, Dominic
    Ahnert, Jordi Rodon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
    Rosenberg, Jonathan
    Sabatier, Renaud
    Viceneux, Armelle
    Rouge, Thibault De la Motte
    Champiat, Stephane
    Lebellec, Loic
    Barthelemy, Philippe
    Sonpavde, Guru
    Gao, Xin
    Niglio, Scot
    Zhang, Tian
    Gedye, Craig
    Galsky, Matthew
    Milowsky, Matthew
    Reimers, Melissa
    Weickhardt, Andrew
    Grande, Enrique
    Castellano, Daniel E.
    Bilen, Mehmet
    Patnaik, Amita
    Zerbib, Robert
    Balbas, Minna
    Xu, Xiaojian
    Aptaker, Kaitlyn
    Balar, Arjun V.
    Awada, Ahmad H.
    CANCER RESEARCH, 2024, 84 (07)
  • [30] NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors (Trial in Progress)
    Baldini, C.
    Patnaik, A.
    Lakhani, N.
    Call, J.
    Galsky, M.
    Garmezy, B.
    Wei, A.
    Carter, L.
    Powles, T.
    Siefker-Radtke, A.
    O'Donnell, P. H.
    Kitano, S.
    Castellano, D. E.
    Shinde, R.
    Joshua, A. M.
    Balbas, M.
    Han, H.
    Chang, A. E.
    Gao, X.
    Iyer, G.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S66 - S66
1234